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Current treatment options for head and neck squamous cell carcinoma (HNSCC) patients 
are often ineffective due to tumor-localized and systemic immunosuppression. Using 
the 4-NQO mouse model of oral carcinogenesis, this study showed that premalignant 
oral lesion cells produce higher levels of the immune modulator, PGE2, compared to 
HNSCC cells. Inhibiting prostaglandin production of premalignant lesion cells with the 
 pan-cyclooxygenase inhibitor indomethacin stimulated their induction of spleen cell 
cytokine production. In contrast, inhibiting HNSCC prostaglandin production did not 
stimulate their induction of spleen cell cytokine production. Treatment of mice bearing 
premalignant oral lesions with indomethacin slowed progression of premalignant oral 
lesions to HNSCC. Flow cytometric analysis of T cells in the regional lymph nodes of 
lesion-bearing mice receiving indomethacin treatment showed an increase in lymph node 
cellularity and in the absolute number of CD8+ T cells expressing IFN-γ compared to 
levels in lesion-bearing mice receiving diluent control treatment. The cytokine-stimulatory 
effect of indomethacin treatment was not localized to regional lymph nodes but was also 
seen in the spleen of mice with premalignant oral lesions. Together, these data suggest 
that inhibiting prostaglandin production at the premalignant lesion stage boosts immune 
capability and improves clinical outcomes.
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inTrODUcTiOn
The 5-year survival rate for patients with head and neck squamous cell carcinoma (HNSCC) remains 
at ~50% (1). Traditional treatments for HNSCC patients, including surgical resection and chemo-
radiation, often fail due to the high incidence of cancer recurrence. There exists a critical need for 
more effective therapies, and there has been a recent interest in incorporating immunotherapies in 
the treatment plan for patients with HNSCC. However, the effectiveness of immunotherapy may be 
compromised by the pronounced immune inhibition in HNSCC patients (2–4). Established HNSCC 
tumors use a variety of mechanisms to thwart the T cell-mediated antitumor response, including 
downregulation of MHC-II molecule expression, upregulation of death ligand expression (FasL) 
and direct secretion of several immunosuppressive molecules, including TGF-β and PGE2 (5, 6).
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The role of PGE2 in the tumor environment is multifold. 
PGE2 has been shown to promote tumor cell growth and inva-
siveness and to also contribute to tumor angiogenesis (7–10). 
Increased levels of tumor-localized cyclooxygenase-2 (COX-2), 
the enzyme responsible for increased PGE2 production, are 
associated with increased levels of immunosuppressive cells 
at the tumor site and a worse prognosis in patients with oral 
cancer (4, 11–14). PGE2 has been shown to directly inhibit T cell 
proliferation and IFN-γ production, and to skew responses 
toward a Th2 phenotype (15). Tumor-derived PGE2 has also 
been shown to chemoattract immune inhibitory cells, such as 
MDSC (16). In some types of malignancies, PGE2 has been 
shown to induce immune cell production of IL-10 and directly 
suppress the production of proinflammatory cytokines by CD4+ 
T cells (4, 15, 17). In several murine and hamster models of 
head and neck cancer, administration of the COX-2 inhibitor 
celecoxib decreased expression of vascular endothelial growth 
factor (VEGF) and survivin, increased tumor cell apoptosis and 
decreased tumor growth (18–20). A few studies have shown 
clinical responses resulting from COX inhibition in HNSCC 
patients (21, 22). In a model of lung carcinoma, inhibition of 
COX-2 resulted in increased antitumor reactivity by shifting 
the cytokine balance of resident immune cells toward a more 
proinflammatory, Th1-like phenotype, as characterized by 
increased IL-12 production and decreased IL-10 production 
(23). While, the immune modulating role of PGE2 in the tumor 
environment has been studied, its role in immune modulation 
as premalignant oral lesions progress to HNSCC tumors has not 
been previously investigated.
Using the 4-NQO mouse model of oral carcinogenesis, our 
prior studies had demonstrated significant immune changes 
at the premalignant lesion stage, before HNSCC tumors are 
established (24). The 4-NQO mouse model is based on the 
carcinogenic effects of 4-NQO, which mimics the effects of 
tobacco at the molecular level and produces all stages of oral 
carcinogenesis (25, 26). Cervical lymph nodes of mice with 
4-NQO induced premalignant lesions have been characterized 
to have increased levels of stimulatory/inflammatory cells and 
cytokines, compared to lymph nodes of both control mice and 
HNSCC-bearing mice (24). In contrast, tumor-draining lymph 
nodes of HNSCC-bearing mice contain increased levels of 
immunosuppressive Foxp3+ T regulatory cells and functionally 
compromised conventional T cells. These studies suggest that an 
activated T cell response is occurring at the premalignant lesion 
stage that wanes as the immunosuppressive environment of 
HNSCC is established. The premalignant lesion cells contribute 
to the inflammatory phenotype by their production of G-CSF, 
RANTES, MCP-1, and PGE2 (27). Because of the progressive 
nature of this model, which spans from premalignant oral lesions 
to HNSCC, investigation into the immune environment during 
the course of progression is possible.
The current study aimed to investigate the effect of inhibiting 
PGE2 production in mice with 4-NQO-induced premalignant oral 
lesions on tumor progression and T cell reactivity. These studies 
showed that administration of indomethacin, a pan-COX inhibi-
tor, to mice with premalignant oral lesions increased immune cell 
cytokine production and improved clinical outcomes.
MaTerials anD MeThODs
Oral carcinogenesis Model
Two-month-old female C57BL/6 mice (Charles Rivers 
Laboratory, Wilmington, MA, USA) were administered 4-NQO 
at a final concentration of 50 μg/ml in their drinking water until 
the development of premalignant oral lesions. Premalignant oral 
lesions typically appear on the tongue at 6–8 weeks of 4-NQO 
treatment and gradually progress to HNSCC. To monitor lesion 
development, mice were examined endoscopically weekly using 
a Stryker 1.9 mm × 30°mm endoscope and images were taken 
using a Stryker 1088 camera (Kalamazoo, MI, USA). During 
the procedure, mice were sedated with inhaled isoflurane 
(Piramal Healthcare, Boise, ID, USA). All animal procedures 
were conducted under the approval of the Institutional Animal 
Care and Use Committee (IACUC) of the Ralph H. Johnson VA 
Medical Center. All study procedures were in compliance with 
institutional and federal guidelines regulating the care and use of 
laboratory animals in research.
culture Medium
Cell culture media consisted of 1× DMEM (Life Technologies, 
Grand Island, NY, USA) containing 4.5  g/l d-glucose and 
l-glutamine, supplemented with 10% fetal bovine serum (FBS) 
and 1× antibiotic antimycotic solution, containing penicillin, 
streptomycin, and amphotericin B (Sigma, St. Louis, MO, USA). 
To establish cell lines from premalignant lesions and HNSCC 
tumors, culture media was supplemented with 2× antibiotic 
antimycotic solution for the first 2 weeks of culture.
Premalignant lesion and  
hnscc Primary cell lines
Primary cell lines were established, as previously described (27) 
by excising 4-NQO-induced premalignant lesions or HNSCC 
from the tongues of premalignant lesion- or HNSCC-bearing 
mice at the appropriate stage, as defined through histopathologi-
cal analysis by the oral pathology section in the Center for Oral 
Health Research at the Medical University of South Carolina. 
Briefly, excised premalignant lesions or HNSCC tumors were 
placed into culture and, once adherent cells became established, 
non-adherent cells were removed. Prior to defining cells as pre-
malignant or HNSCC, their epithelial phenotype was confirmed, 
as well as uniformity of their microscopic and growth character-
istics. Supernatants were collected from sub-confluent cultures 
(80%) after 48 h and used in the specific analyses described below.
spleen cell Preparation
Spleens were harvested from healthy control C57BL/6 mice 
and homogenized using a glass homogenizer. Cells were passed 
through a 70 μm cell strainer (BD Falcon, San Jose, CA, USA) and 
rinsed with HBSS (Life Technologies, Grand Island, NY, USA). 
Red blood cells were lysed by adding ACK Lysing Buffer (Lonza, 
Walkersville, MD, USA) for 3 min. Splenocytes were then washed 
twice with HBSS. Cell number was determined by counting cells 
excluding trypan blue using a hemocytometer.
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spleen cell culture with supernatants of 
indomethacin-Treated Premalignant 
lesion cells or hnscc cells
Premalignant lesion cells and HNSCC cells were cultured for 24 h 
at 37°C at 1 ×  106  cells/well in 12-well tissue culture plates in 
fresh media with or without 6 μg/ml indomethacin, as previously 
described (28). Supernatants were then collected for culture with 
spleen cells. Spleen cells from healthy control C57BL/6 mice 
were cultured for 72 h at 37°C with diluted (1:2 in fresh medium) 
supernatants collected from indomethacin- or diluent control-
treated premalignant lesion cells and HNSCC cells at 1 × 106 cells/
well in 12-well anti-CD3-coated tissue culture plates with 30 IU 
mouse IL-2. Controls consisted of splenocytes cultured for 72 h 
at 37°C in fresh medium, with or without 6 μg/ml indomethacin. 
Supernatants were collected from the spleen cell cultures and the 
levels of cytokines were quantitated. Also quantitated were levels 
of cytokines or PGE2 in the media conditioned by premalignant 
lesion cells or HNSCC prior to its addition to the spleen cells.
Quantitation of secreted cytokines by 
cytokine Bead array
All reagents used for the cytokine bead array were from BD 
Biosciences (San Jose, CA, USA). The levels of IFN-γ, IL-2, 
IL-17A, IL-6, TNF-α, and IL-10 in cell culture supernatants were 
determined using a mouse cytometric bead array Th1/Th2/Th17 
cytokine kit. A FACS Canto (BD Biosciences) flow cytometer 
was used to quantify cytokine profiles and relative amounts of 
each cytokine were analyzed using the FCAP Array Software 
(manufactured by Soft Flow Hungary Ltd. for BD Biosciences). 
Cytokine levels in premalignant lesion cell and HNSCC cell 
supernatants were measured before addition to cultures with 
spleen cells, and these levels were subtracted from the total 
cytokine levels in the supernatants from spleen cells that were 
co-cultured with lesion or HNSCC-conditioned media. Cytokine 
levels from a representative experiment are shown in pg/ml. To 
standardize cytokine levels produced by spleen cells cultured in 
diluent- or indomethacin-containing fresh medium, data from 
five independent experiments run in duplicate are presented as 
fold change/control.
indomethacin Treatment of Premalignant 
lesion-Bearing Mice
Two-month-old female C57BL/6 mice were administered 4-NQO 
in their drinking water until the development of premalignant oral 
lesions (8 weeks), as determined by weekly endoscopic examina-
tion of the oral cavities. At this point, 4-NQO water was removed 
and replaced with drinking water containing either 30  μg/ml 
indomethacin (10 mice) or diluent (1% ethanol) control (10 mice) 
(29). Oral cavities were endoscopically monitored every 10 days 
using a Stryker 1.9 mm ×  30°mm endoscope and lesions were 
counted and scored blindly. Lesion progression was documented 
using a Stryker 1088 camera. At 6 and 20 weeks after beginning 
indomethacin or diluent control treatment, five mice per group 
were sacrificed and cervical lymph nodes were harvested. A 
group of age-matched untreated C57BL/6 healthy control mice 
were also sacrificed at these time points for  collection of cervical 
lymph nodes.
lesion scoring
As part of the endoscopic examination performed every 10 days, 
the oral cavity was photographed. Using the photographic images, 
the total number and gross pathologic score of tongue lesions in 
4-NQO-treated mice receiving either indomethacin or diluent 
control were blindly assessed, as previously described (24, 30). 
Lesions were scored on a 1–4 scale, with 1 indicating a flat macule, 
2 indicating a raised papule, 3 indicating a raised plaque, and 4 
indicating a grossly exophytic lesion.
cervical lymph node cell  
Preparation and culture
Cervical lymph nodes harvested from experimental and control 
C57BL/6 mice were homogenized to a single cell suspension 
using a Stomacher 80 homogenizer (Seward Laboratory Systems, 
Davie, FL, USA), set on high for 90  s. Cells were then passed 
through a 70 μm cell strainer (BD Falcon, San Jose, CA, USA) and 
rinsed with HBSS. Cell number was determined by counting cells, 
excluding trypan blue using a hemocytometer. Cells were cultured 
in 12-well anti-CD3-coated tissue culture plates at 1 × 106 cells/
well in fresh media for 72 h at 37°C. Supernatants were collected 
(500 μl) from each well for cytokine quantitation by cytokine bead 
array. Cells were then restimulated with 2 μl/ml Cell Stimulation 
Cocktail (PMA/ionomycin; eBioscience, San Diego, CA, USA) 
and 0.6 μl/ml GolgiStop (BD Biosciences) for the last 4–6 h of 
culture at 37°C. Cells were gently collected from tissue culture 
plates with 25 cm cell scrapers (Sarstedt, Inc., Newton, NC, USA), 
washed once with stain buffer, and transferred to polystyrene 
tubes at 1 × 106 cells/tube for flow cytometric analysis.
Flow cytometric analysis of cells
All antibodies and reagents used for flow cytometric analysis were 
from BD Biosciences. Spleen cells or cervical lymph node cells 
were suspended in polystyrene tubes at 1 × 106 cells/tube in 300 μl 
buffer, containing 2% FBS in sterile 1× PBS, at 4°C for 15 min and 
then centrifuged at 1,000 rpm for 5 min. Cells were resuspended 
in 10 μl Fc block, containing anti-CD16/CD32 antibody at a 1:100 
dilution in sterile 1× PBS, at 4°C for 10 min to block non-specific 
antibody binding to the cell surface. After washing cells twice, 
they were resuspended in 1 ml cold BD Cytofix, and incubated for 
20 min at 4°C. Cells were washed twice, resuspended in 50 μl BD 
Perm/wash buffer and incubated for 30 min at room temperature 
with equal concentrations of antibodies or appropriate isotype 
controls: FITC-CD4, APC-CD8a, and PerCP-Cy5.5-IFN-γ. After 
incubation with antibodies, cells were washed twice in BD Perm/
wash buffer and resuspended in 400 μl BD stain buffer for analysis 
of the extent and frequency of positive-staining cells using a BD 
FACS Canto flow cytometer.
statistical analyses
Data were reported using the mean as a measure of central ten-
dency ± SEM. To compare one variable condition between groups, 
a one-way ANOVA analysis was initially performed (GraphPad 
TaBle 1 | Pretreatment of premalignant lesion cells with indomethacin skews their induction of spleen cell cytokine production.
cytokine (pg/ml) Media Media + indo PM PM + indo hnscc hnscc + indo
IL-2 181.5 ± 5.1 166.2 ± 4.1 258.5 ± 7.8 314.2 ± 5.6 178.9 ± 6.3 165.7 ± 2.8
p = 0.0575 **p = 0.0012 p = 0.1069
IFN-γ 94.8 ± 2.3 92.7 ± 1.5 483.2 ± 33.9 631.4 ± 20.2 139.5 ± 11.9 106.8 ± 2.9
p = 0.4716 **p = 0.0095 *p = 0.0365
TNF-α 45.5 ± 1.3 43.6 ± 1.1 495.9 ± 14.7 470.9 ± 8.7 67.9 ± 4.0 60.3 ± 2.7
p = 0.3136 p = 0.1941 p = 0.1697
IL-6 4.7 ± 0.7 3.2 ± 0.6 245.3 ± 8.9 243.8 ± 2.3 3.1 ± 1.1 3.4 ± 0.4
p = 0.1477 p = 0.8718 p = 0.8034
IL-10 2.6 ± 1.6 0.9 ± 0.9 52.0 ± 1.4 77.3 ± 1.1 6.3 ± 1.1 5.0 ± 1.7
p = 0.3866 ***p < 0.0001 p = 0.5423
IL-17A 11.3 ± 0.7 10.8 ± 0.6 35.0 ± 0.4 17.0 ± 0.2 17.3 ± 0.4 6.4 ± 1.0
p = 0.6005 ***p < 0.0001 ***p < 0.0001
Spleen cells from healthy control C57BL/6 mice were cultured for 72 h with media conditioned by premalignant lesion cells or HNSCC cells that were treated with diluent or  
6 μg/ml indomethacin. Supernatants were collected for cytokine measurement. Results are from a representative experiment performed in duplicate. Data are presented 
as picogram per milliliter and represent mean ± SEM. Significant values are indicated as follows: *p < 0.05, **p < 0.01, and ***p < 0.0001 (two-tailed Student’s t-test). PM, 
premalignant; HNSCC, head and neck squamous cell carcinoma; indo, indomethacin.
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Prism version 6.03 for Windows, GraphPad Software, La Jolla, 
CA, USA). If differences were identified by the ANOVA analysis, 
a two-tailed Student’s t-test or Mann–Whitney U test was then 
performed to determine significance of differences between each 
of two groups (e.g., control vs. premalignant, control vs. HNSCC, 
premalignant vs. HNSCC, and indomethacin vs. diluent control) 
using the GraphPad Prism version 6.03. Cohen’s d was used as 
the effect size measure for the Student’s t-test or Mann–Whitney 
U test. Significance was reported in the 95% confidence interval.
resUlTs
Pretreatment of Premalignant Oral lesion 
cells with indomethacin skews Their 
cytokine-inducing Phenotype
One mechanism by which PGE2 impacts on immune reactivity 
in the tumor environment is by skewing immune cell cytokine 
production away from a Th1-type response (15, 17). To inves-
tigate how inhibiting PGE2 impacts on immune cell cytokine 
production in the premalignant oral lesion environment, spleen 
cells from healthy C57BL/6 mice were cultured with media condi-
tioned by supernatants from indomethacin-treated premalignant 
lesion cells or HNSCC cells. The levels of cytokines produced by 
spleen cells (picogram per milliliter) are shown in Table  1. To 
more clearly represent the impact of indomethacin treatment 
on cytokine skewing by premalignant lesion cells and HNSCC 
cells, and to control for the impact of indomethacin on spleen cell 
cytokine production in control conditions, levels of cytokines in 
these cultures were normalized to the levels produced by spleen 
cells in the presence of equal concentrations of indomethacin in 
media alone (Figure 1).
As shown in Table  1, media conditioned by premalignant 
lesion cells increased spleen cell production of the Th1 media-
tors IL-2 (p = 0.0002) and IFN-γ (p < 0.0001), the inflammatory 
mediators TNFα (p <  0.0001), IL-6 (p <  0.0001), and IL-17A 
(p <  0.0001), and the inhibitory mediator IL-10 (p <  0.0001) 
compared to media conditioned by HNSCC cells or media 
alone. Treatment of premalignant lesion cells and HNSCC cells 
with indomethacin significantly reduced their PGE2 production 
(Figure  1A). Indomethacin treatment of premalignant lesion 
cells further increased their induction of spleen cell production 
of Th1-associated cytokines IL-2 and IFN-γ (Figure  1B and 
Table  1). While media of indomethacin-treated premalignant 
lesion cells also increased spleen cell production of the inflamma-
tory mediator IL-6, this difference was not statistically significant. 
Media conditioned by both premalignant lesion cells and HNSCC 
increased spleen cell production of IL–17A, but this stimulation 
was blocked, when premalignant lesion cells and HNSCC were 
treated with indomethacin. Interestingly, indomethacin treat-
ment of premalignant lesion cells enhanced their stimulation of 
spleen cell production of IL-10, suggesting that inhibiting PGE2 
production may also boost Th2-associated activity. With the 
exception of IL-17A, media conditioned by HNSCC cells did not 
impact on spleen cell production of any of the other cytokines, 
regardless of whether the HNSCC cells had been treated with 
diluent or with indomethacin. Overall, the data show that inhib-
iting prostaglandin production impacts on the premalignant 
lesion environment, boosting Th1- and Th2-associated cytokine 
secretion by immune cells.
administration of indomethacin to Mice 
with 4-nQO-induced Premalignant 
lesions improves clinical Outcome
Because inhibiting prostaglandin production by premalignant 
lesion cells resulted in their induction of increased cytokine 
production by immune cells, we sought to determine whether 
treating mice bearing 4-NQO-induced premalignant lesions 
with indomethacin to inhibit prostaglandin production would 
slow progression to tumor. For this study, 4-NQO was admin-
istered to 2-month-old C57BL/6 mice until the development 
of premalignant lesions, at which point the administration of 
indomethacin or diluent control was initiated and continued for 
20 weeks (Figure 2A). To monitor the progression of premalig-
nant lesions to HNSCC during the course of treatment, mice were 
FigUre 1 | Pretreatment of premalignant lesion cells with indomethacin skews their induction of spleen cell cytokine production toward increased 
production of Th1-associated cytokines and decreased production of il-17a. (a) Premalignant lesion cells (PM) and HNSCC cells were plated at 
1 × 106 cells/well and treated with 6 μg/ml indomethacin (indo) for 24 h. The levels of PGE2 in cell supernatants were measured by ELISA. (B) Spleen cells from 
healthy control C57BL/6 mice were cultured for 72 h with media conditioned by premalignant lesion cells or HNSCC cells that were treated with diluent or 6 μg/ml 
indomethacin. Supernatants were collected for cytokine measurement. Cytokine levels were standardized to levels produced by spleen cells cultured in diluent- or 
indomethacin-containing fresh medium instead of conditioned media and, thus, data are shown as fold change/control. Results are from five independent 
experiments, each run in duplicate. Data represent mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001 (two-tailed Student’s t-test).
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examined by endoscopy every 10 days. The images captured of 
the oral cavity were stored and used for scoring the lesions in a 
double-blind manner. As shown in Figure 2B, mice that received 
indomethacin treatment from the time that their premalignant 
lesions were detectable had a significantly better overall clinical 
outcome compared to lesion-bearing mice receiving diluent 
control treatment. At the endpoint of the study (day 139, about 
20 weeks post-initiation of indomethacin treatment), the average 
lesion score for mice receiving indomethacin was 1.9, whereas the 
average lesion score for mice receiving diluent control was 3.4. 
Differences in clinical outcome were more striking at later time 
points as opposed to earlier in the course of treatment. Although, 
the lower score for lesions of indomethacin-treated mice as com-
pared to lesion scores for diluent control-treated mice was seen 
during most of the treatment period, the differences were only 
statistically significant toward the latter period of treatment. For 
these latter time points, the effect sizes (Cohen’s d) were moderate 
to large, ranging from 0.422 on day 90 to 2.15 on day 120. Shown 
FigUre 2 | administering indomethacin to mice with 4-nQO-induced premalignant lesions slows progression to hnscc. (a) Indomethacin or diluent 
control was administered in the drinking water of mice with 4-NQO-induced premalignant oral lesions starting from when premalignant oral lesions were 
endoscopically detectable. (B) Endoscopic images of oral cavities were captured every 10 days and lesions were scored 1–4. (c) Lesion scores for each mouse at 
indicated time points. (D) Images of the oral cavity of a representative mouse from each group. Lesion score data represent mean ± SEM. Shown in (c,D) are lesion 
scores and endoscope images for mice scored at baseline and at days 13 (1.9 weeks), 33 (4.7 weeks), 70 (10 weeks), 104 (14.9 weeks), and 139 (19.9 weeks) after 
initiating indomethacin treatment. *p < 0.05 (Mann–Whitney U test).
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FigUre 3 | effect of administering indomethacin to mice with 4-nQO-induced premalignant lesions on cellularity of cervical lymph nodes. Cervical 
lymph nodes (CLN) from mice receiving indomethacin or diluent control treatments were harvested at baseline, 6 and 20 weeks post-initiation of treatment. Lymph 
nodes were dissociated to single cell suspensions and the number of trypan blue-excluding cells was counted. Results are from five mice per group per time point. 
Data represent mean ± SEM. *p < 0.05 (two-tailed Student’s t-test).
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in Figure 2C are scores for each individual mouse at various time 
points during the course of treatment. By the endpoint of the study 
(day 139) two mice in the diluent control group had progressed 
to advanced HNSCC (score  =  4), bearing exophytic tumors, 
whereas no mice in the indomethacin group progressed to this 
stage during the study (Figure 2C and examples in Figure 2D). 
Furthermore, 4 of the 5 mice in the diluent control group had 
lesion scores of 3 or higher at the endpoint of the study, compared 
to one mouse in the indomethacin group. These data show that 
administering indomethacin to mice with 4-NQO-induced 
premalignant lesions slows progression to HNSCC.
effect of administering indomethacin to 
Mice with 4-nQO-induced Premalignant 
lesions on cellularity of cervical lymph 
nodes
Previous studies had shown that the cervical lymph nodes of mice 
with 4-NQO-induced HNSCC tumors undergo hyperplasia (24). 
The current study sought to determine if indomethacin treatment 
impacted on the total cellularity of cervical lymph nodes, as 
premalignant lesions progressed to HNSCC. As seen in Figure 3, 
there were no differences in the total number of cervical lymph 
node cells in healthy control and premalignant lesion-bearing 
mice at the onset of indomethacin treatment, when premalignant 
oral lesions were initially detected (baseline). At 6 weeks of treat-
ment, the number of lymph node cells in premalignant lesion-
bearing mice that were treated with either diluent control or 
indomethacin was increased compared to the number in healthy 
control mice. The effect size was strong for both control vs. dilu-
ent control (1.27) and control vs. indomethacin (1.36). These data 
suggest that regional lymph nodes exhibit hyperplasia during the 
progression of premalignant oral lesions toward HNSCC. At the 
endpoint of the study (20  weeks of treatment), the total num-
ber of cervical lymph node cells in indomethacin-treated mice 
remained increased compared to healthy control mice (Cohen’s 
d = 1.872), whereas the number of lymph node cells in lesion-
bearing mice treated with diluent control declined compared to 
the 6-week time point. The differences in cellularity of lymph 
nodes from diluent- vs. indomethacin-treated mice did not reach 
statistical significance, but these data nevertheless show increased 
lymph node cellularity in mice bearing premalignant lesions and 
a decline in this cellularity as lesions progress to cancer.
effect of administering indomethacin to 
Mice with 4-nQO-induced Premalignant 
lesions on the Percentage and absolute 
number of cD8+ T cells expressing iFn-γ 
in the cervical lymph nodes
Our studies described above (Figure 1) showing that inhibiting 
prostaglandin production by premalignant lesion cells leads 
to their induction of T cell cytokine production prompted 
studies to determine the impact of indomethacin treatment of 
premalignant lesion-bearing mice on the production of IFN-γ 
by their lymph node cells. Indomethacin or diluent control was 
administered to premalignant lesion-bearing mice. Cervical 
lymph node cells were then analyzed for both the frequency and 
absolute numbers of T cells expressing IFN-γ at 6 and 20 weeks 
post-initiation of treatment (Figure 4). At baseline, there was a 
trend (not significant) toward increased percentages of CD4+ and 
CD8+ T cells expressing IFN-γ (Figure  4A), but no difference 
in absolute numbers of these cells (Figure  4B) in the cervical 
lymph nodes of premalignant lesion-bearing mice compared to 
the lymph nodes of healthy control mice. At 6 weeks after onset 
of treatment, the percentage (Figure 4C) and, more prominently, 
the absolute number (Figure  4D) of CD4+ and CD8+ T cells 
expressing IFN-γ was increased in premalignant lesion-bearing 
mice, regardless of whether they were treated with control diluent 
or indomethacin. The effect size was large for both control vs. 
diluent control (Cohen’s d = 1.30) and control vs. indomethacin 
(Cohen’s d =  1.59). However, at 20  weeks, the percentages of 
CD4+ and CD8+ cells expressing IFN-γ in lymph node cells of 
lesion-bearing mice declined (Figure  4E). However, there was 
an increase in the absolute number of CD8+ cells expressing 
IFN-γ, which was more prominent for indomethacin-treated 
FigUre 4 | administering indomethacin to mice with 4-nQO-induced premalignant lesions increases the number of iFn-γ-expressing cD8+ T cells in 
cervical lymph nodes. Graphical representation of the percentage and the absolute number of IFN-γ-expressing cervical lymph node cells of healthy control mice 
and premalignant lesion-bearing mice at baseline (a,B) and of premalignant lesion-bearing mice receiving indomethacin or diluent control treatment for 6 (c,D) and 
20 weeks (e,F). Five mice were examined for each group per time point. The absolute number of positive-staining cells was calculated by multiplying percent 
positive cells by the number of cervical lymph node cells for each mouse. Data represent mean ± SEM. *p < 0.05 (two-tailed Student’s t-test).
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mice (Figure 4F, Cohen’s d = 1.34 for control vs. indomethacin). 
These results indicate a progressive increase in the number of 
IFN-γ-expressing CD8+ lymph node cells in mice bearing prema-
lignant lesions from baseline to 6 and 20 weeks of indomethacin 
treatment.
effect of administering indomethacin to 
Mice with 4-nQO-induced Premalignant 
lesions on Their spleen cell cytokine 
Production
While the above studies assessed the impact of treating pre-
malignant lesion-bearing mice with indomethacin on regional 
lymph node cell expression of IFN-γ, studies were conducted to 
determine if there was a systemic effect on cytokine production. 
This was accomplished by measuring levels of cytokines secreted 
by spleen cells of premalignant lesion-bearing mice after 6 and 
20 weeks of diluent or indomethacin treatment. Whereas, spleen 
cells from diluent control-treated lesion-bearing mice produced 
lower levels of IFN-γ compared to spleen cells from healthy 
control mice at the endpoint of the study, treatment with indo-
methacin enhanced their production of IFN-γ (Table 2). Analysis 
of the systemic effects of COX inhibition was expanded to include 
earlier time points of indomethacin treatment (Figures  5A–D, 
fold change/control = 1). Production of IL-2 by spleen cells of 
mice bearing premalignant oral lesions was similar to that by 
spleen cells of healthy control mice. This production of IL-2 
by spleen cells of mice with premalignant oral lesions was not 
significantly affected by treating the mice for either 6 or 20 weeks 
with indomethacin or diluent control (Figure 5A). In contrast, 
TaBle 2 | impact of administering indomethacin to mice with  
4-nQO-induced premalignant lesions on spleen cell cytokine production.
cytokine  
(pg/ml)
control 4-nQO + diluent  
control
4-nQO + indomethacin
IL-2 120.1 ± 14.7 122.0 ± 4.1 117.9 ± 4.2
p = 0.4945
IFN-γ 57.2 ± 8.7 41.5 ± 5.0 71.9 ± 18.3
p = 0.1271
IL-17A 7.9 ± 1.2 6.8 ± 1.1 5.1 ± 1.4
p = 0.3369
TNF-α 27.1 ± 3.1 20.7 ± 1.4 22.0 ± 3.8
p = 0.7471
Spleens from mice receiving indomethacin or diluent control treatments were collected 
at study endpoint (20 weeks post-initiation of treatment). Spleen cells were cultured for 
72 h at 1 × 106 cells/well and supernatants were collected for quantitation of secreted 
IL-2, IFN-γ, IL-17A, and TNF-α. Five mice were examined for each group. Spleen cells 
from untreated healthy control C57BL/6 mice served as controls. Data are presented 
as pg/ml and represent mean ± SEM (two-tailed Student’s t-test).
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the level of IFN-γ produced by spleen cells of diluent-treated 
mice bearing premalignant oral lesions was reduced at both 6 
and 20 weeks compared to levels of IFN-γ produced by spleen 
cells of healthy control mice (Figure 5B). Treating lesion-bearing 
mice with indomethacin increased their spleen cell production 
of IFN-γ compared to the amount produced by spleen cells from 
diluent control-treated mice or from healthy control mice at 
both 6 and 20 weeks post-initiation of treatment. The effect size 
for the level of IFN–γ in diluent control vs. indomethacin was 
moderately strong (d = 0.774 at 6 weeks, d = 0.540 at 20 weeks). 
The level of IL-17A produced by spleen cells of either diluent- or 
indomethacin-treated mice bearing premalignant lesions was 
reduced compared to levels produced by healthy control mice, 
especially at the 6-week time point (Figure 5C). Although not 
statistically significant, IL-17A production by spleen cells of mice 
receiving indomethacin tended to be further decreased compared 
to the level produced by spleen cells of mice receiving diluent 
control treatment (Cohen’s d = 0.429 at 6 weeks). Premalignant 
lesion-bearing mice that were treated with diluent control 
produced similar levels of TNF-α as did spleen cells of healthy 
control mice (Figure  5D). Indomethacin treatment increased 
TNF-α production by spleen cells of premalignant lesion-bearing 
mice at 6 weeks post-onset of treatment, although this difference 
was not evident 20 weeks post-onset of treatment. Overall, these 
data indicate that presence of premalignant oral lesions can 
alter cytokine production not only in regional lymph node cells, 
but also in the spleen. They also show that administering indo-
methacin to mice with 4-NQO-induced oral lesions can enhance 
production of select Th1/inflammatory mediators.
DiscUssiOn
Patients with established HNSCC tumors exhibit pronounced 
immune suppression (2–4). COX-2 expression is upregulated in 
HNSCC tumors and a few studies have pointed toward PGE2 as a 
contributor to the immunosuppressive environment of HNSCC 
(4, 11–14). COX-2 inhibitors are being explored as possible adju-
vants to traditional therapies for HNSCC patients. In a few clinical 
trials, administration of celecoxib as an adjuvant therapy has 
been associated with significant response rates (22, 31, 32). One 
retrospective study looking at the relationship between the use 
of non-selective cyclooxygenase inhibitors and overall survival 
in HNSCC patients found that median survival was increased 
among COX inhibitor users, although the regimen/type of COX 
inhibitor use was not controlled for in this study (21). A critical 
gap remains in our knowledge of how COX inhibition impacts on 
the T cell responses in HNSCC patients. Furthermore, the role of 
PGE2 in the premalignant lesion environment has not been previ-
ously defined. Our studies suggest that PGE2 may be playing an 
immune modulatory role before HNSCC tumors are established, 
and that there may be a critical window during the premalignant 
lesion stage in which COX inhibitors can be administered to 
facilitate cytokine responses and slow progression to tumor.
Previously, our lab had shown that premalignant lesion cells 
established from the 4-NQO murine model of oral carcinogenesis 
secrete increased levels of several immune modulating factors, 
including PGE2, compared to HNSCC cells (27). The current 
study shows that treatment of premalignant lesion cells with 
indomethacin, a pan-COX inhibitor, increased their induction of 
spleen cell production of Th1-associated cytokines. In contrast, 
treatment of HNSCC cells with indomethacin did not increase 
their induction of spleen cell Th1-type cytokines, suggesting that 
it may be more feasible for PGE2 inhibitors to stimulate Th1-type 
immune responses in the premalignant lesion environment. 
Inhibiting prostaglandin production by premalignant lesion cells 
also led to their induction of spleen cell production of IL-10, so the 
effect of indomethacin treatment cannot be classified singularly 
as “pro-Th1.” The concurrent increase in IL-10 may be explained 
as a consequence of an initial increase in Th1-type cytokines, as 
a mechanism to “turn off ” the inflammatory response, or PGE2 
may be altering the production of both Th1-type and Th2-type 
cytokines in the premalignant lesion environment. To further 
delve into the mechanism by which COX inhibition impacts on 
T cell activity, future studies should include phenotypic analysis 
of CD4+ and CD8+ T cells by flow cytometry.
PGE2 has been shown to play an immunosuppressive role by 
multiple means. In the tumor environment, PGE2 has been shown 
to directly suppress macrophage function and inhibit IL-12 secre-
tion by dendritic cells, resulting in a Th2-skewing of mature helper 
T cells (33–37). Furthermore, PGE2 has been shown to directly 
inhibit IL-2 and IFN-γ production by antigen-specific T  cells 
(38, 39). Aside from direct immune inhibition, PGE2 also func-
tions to recruit and sustain a population of MDSCs in the tumor 
environment, which secrete immunosuppressive molecules and 
also function to inhibit the T cell response (40–42). In a model 
of lung carcinoma, inhibiting PGE2 production led to a shift in 
cytokine production by T cells toward a more Th1-type response 
and decreased tumor burden (23). Because earlier studies in our 
lab had shown that significant immune changes take place at the 
premalignant lesion stage (24, 27, 43), the current study sought to 
determine how inhibiting PGE2 production at this stage impacts 
on T cell reactivity and progression to HNSCC. Administration 
of indomethacin, a pan-COX inhibitor, to mice with 4-NQO-
induced premalignant lesions slowed progression of lesions to 
cancer. To analyze how indomethacin treatment impacts on the 
FigUre 5 | administering indomethacin to mice with 4-nQO-induced premalignant lesions increases spleen cell cytokine production at 6 and 
20 weeks post-onset of treatment. Spleens from mice receiving indomethacin or diluent control treatments were collected at 6 and 20 weeks after onset of 
diluent control or indomethacin treatment. Spleen cells were cultured for 72 h at 1 × 106 cells/well and supernatants were collected for quantitation of secreted IL-2 
(a), IFN-γ (B), IL-17A (c), and TNF-α (D). Five mice were examined for each group per time point. Spleen cells from untreated healthy control C57BL/6 mice served 
as controls. Data are shown as fold change from values for spleen cells from healthy control mice. Data represent mean ± SEM (two-tailed Student’s t-test).
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local immune response, T cells from cervical lymph nodes of 
indomethacin- vs. diluent control-treated mice were analyzed 
for IFN-γ expression. Mice receiving indomethacin treatment 
had an increase in the number of CD8+IFN-γ+ T  cells in the 
cervical lymph nodes, which became more prominent with a 
more prolonged period of indomethacin treatment. These data 
suggest that COX inhibition at the premalignant lesion stage 
sustains the activation of tumor-localized T cells and may be a 
mechanism by which administration of indomethacin resulted 
in a significantly improved clinical response. Administration of 
indomethacin at the premalignant lesion stage also impacted on 
the systemic immune response, although to a lesser extent. Spleen 
cells from indomethacin-treated mice secreted increased levels of 
IFN-γ and TNF-α compared to spleen cells from control-treated 
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mice, at 6 weeks post-treatment, suggesting that indomethacin 
also induces a systemic Th1-type response. At 20  weeks post-
treatment, spleen cell IFN-γ secretion remained higher in the 
indomethacin-treated group, suggesting that, as observed in the 
cervical lymph nodes, a more prolonged period of indomethacin 
treatment is associated with an activated Th1-type response. 
Overall, the data show that administration of indomethacin to 
mice with 4-NQO-induced lesions significantly improves clinical 
outcome and results in sustained T cell cytokine production in 
regional lymph nodes and spleen.
Future studies with larger cohorts of mice will be necessary 
to investigate the role of PGE2 in modulating T cell activity as 
premalignant lesions progress to tumor. Flow cytometric analysis 
of T cells in the cervical lymph nodes of indomethacin-treated 
vs. diluent control-treated lesion-bearing mice should be 
expanded in the future to include Th2-associated IL-4 and IL-10, 
Th17-associated IL-17A and CD8+ T cell-associated granzyme 
B to further delineate the impact of prostaglandins on T cell 
cytokine and protease production in mice with premalignant oral 
lesions. Proliferation in responses to lesion or tumor antigens by 
isolated CD4+ and CD8+ T cells from the cervical lymph nodes 
of indomethacin-treated vs. diluent control-treated mice would 
also provide insight into the mechanism of how inhibiting PGE2 
production at the premalignant lesion stage impacts on the anti-
lesion or antitumor response.
The origination of oral cancer often can be detected as 
leukoplakias or erythroplakias, commonly developing on the 
tongue and floor of mouth. Studies in the 4-NQO model of oral 
carcinogenesis show that premalignant lesion cells themselves 
produce mediators, including PGE2, which may be modulating 
the immune response well before HNSCC is established. The 
current study suggests that, inhibiting PGE2 production at the 
premalignant lesion stage may have the capacity to sustain a 
Th1-type immune response and to slow progression to tumor. 
Importantly, the current study suggests that, administration of 
immunotherapies, such as COX-2 inhibitors, to patients with 
premalignant lesions may boost the antitumor response and 
improve clinical outcomes.
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